Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ING-1(heMAb)
ING-1 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ING-1(heMAb) | DRUG | - |
Inclusion Criteria 1. Subject has adenocarcinomas of the ovary, breast, lung, prostate, colon or rectum. 2. Subject has an advanced metastatic adenocarcinoma that is either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist. 3. Subject has ...
ING-1 is an investigational monoclonal antibody that was studied for the treatment of advanced adenocarcinomas, a type of cancer that forms in glandular tissue. It was evaluated in a Phase 1 clinical trial in adults with advanced adenocarcinoma. ING-1 is not an approved therapy and remains an investigational agent.
ING-1 targets EPCAM, also known as the epithelial cell adhesion molecule. EPCAM is a cell surface antigen expressed on epithelial cells and many adenocarcinomas. By binding EPCAM, ING-1 is designed to act against tumor cells of epithelial origin. ING-1 is a monoclonal antibody developed as an oncology therapeutic.
ING-1 is associated with XOMA Royalty Corporation, which trades on the Nasdaq under the ticker XOMA. XOMA Royalty Corporation is the developer listed for this monoclonal antibody asset. ING-1 is an investigational oncology candidate that has been evaluated in a completed Phase 1 study.
ING-1 is in Phase 1 development. It has completed one Phase 1 clinical trial in patients with advanced adenocarcinomas. ING-1 is an investigational monoclonal antibody and is not an approved product. No active trials of ING-1 are currently listed.
ING-1 was studied in the completed Phase 1 trial NCT00051675, titled Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas. The trial enrolled 30 participants in the United States, included adults 18 years and older of all sexes, and was an uncontrolled, non-randomized study.
Yes, ING-1 is also known as ING-1(heMAb). The two names refer to the same monoclonal antibody asset developed by XOMA Royalty Corporation. ING-1(heMAb) targets EPCAM and was evaluated in a completed Phase 1 trial in advanced adenocarcinomas.